Vitamin K antagonists remain the INVICTUS standard of care for patients with rheumatic heart disease and atrial fibrillation

Comment on the article ‘Rivaroxaban in Rheumatic Heart Disease-Associated Atrial Fibrillation’, presented at the 53rd European Society of Cardiology Congress in August 2022 and simultaneously published inThe New England Journal of Medicine, DOI:10.1056/NEJMoa2209051.
Source: European Heart Journal - Category: Cardiology Source Type: research